{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:28:55Z","timestamp":1787941735084,"version":"build-2784847793"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            This multicenter study evaluated the BD Phoenix Automated Microbiology System STREP panel (BD Diagnostic Systems). Antimicrobial susceptibility testing (AST) with 13 agents was performed on 2,013 streptococci (938\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            isolates; 396 group B streptococci [GBS]; 369 viridans group streptococci [VGS]; 290 beta-hemolytic streptococcus groups A, C, and G; and 20 other streptococci) with the Phoenix system and a broth microdilution reference method. Clinical and challenge isolates were tested against cefepime, cefotaxime (CTX), ceftriaxone (CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezolid, meropenem, penicillin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin. Clinical isolates with major errors or very major errors (VMEs) were retested in duplicate by both methods. The final results for clinical isolates showed the following trends. For all of the organism-antimicrobial agent combinations tested, categorical agreement (CA) was 92 to 100%, with one exception\u2014VGS-PEN (87% CA; all errors were minor). For\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            , there was one major error with CLI (0.1%) and one or two VMEs with CTX (4%), CTR (4.5%), ERY (0.9%), and TET (0.7%). For groups A, C, and G, the CA was 97 to 100% and the only VMEs were resolved by additional reference laboratory testing. For GBS, there was only one VME (TET, 0.3%) and D-zone testing of 23 isolates with CLI major errors (one isolate unavailable) revealed inducible CLI resistance. For VGS, the major error rates were 0 to 3% and VMEs occurred with seven agents (3.5 to 7.1%). The mean times required for organism groups to generate results ranged from 8.4 to 9.4 h. The Phoenix system provided reliable and rapid AST results for most of the organism-antimicrobial agent combinations tested.\n          <\/jats:p>","DOI":"10.1128\/jcm.00981-07","type":"journal-article","created":{"date-parts":[[2007,7,26]],"date-time":"2007-07-26T01:19:01Z","timestamp":1185412741000},"page":"2863-2871","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Multicenter Evaluation of the BD Phoenix Automated Microbiology System for Antimicrobial Susceptibility Testing of\n            <i>Streptococcus<\/i>\n            Species"],"prefix":"10.1128","volume":"45","author":[{"given":"Sandra S.","family":"Richter","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanita J.","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin P.","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Robert Wood Johnson Medical School, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bruckner","sequence":"additional","affiliation":[{"name":"UCLA Healthcare, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet F.","family":"Hindler","sequence":"additional","affiliation":[{"name":"UCLA Healthcare, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Saubolle","sequence":"additional","affiliation":[{"name":"Lab Science of Arizona, Tempe, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary V.","family":"Doern","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.09.016"},{"key":"e_1_3_2_3_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014seventh edition 2006"},{"key":"e_1_3_2_4_2","unstructured":"Performance standards for antimicrobial susceptibility testing; 17th informational supplement M100-S17 2007"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1198-743x.2001.00230.x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.4.891"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/430906"},{"key":"e_1_3_2_8_2","unstructured":"Class II special controls guidance document: antimicrobial susceptibility test (AST) systems; guidance for industry and FDA 2007"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.8.2814-2818.2000"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.12.5928-5930.2004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/313936"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3623-3624.2001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/432473"},{"key":"e_1_3_2_14_2","first-page":"1","volume":"51","year":"2002","unstructured":"Schrag, S., R. Gorwitz, K. Fultz-Butts, and A. Schuchat. 2002. Prevention of perinatal group B streptococcal disease, revised guidelines from CDC. Morb. Mortal. Wkly. Rep.51(RR-11):1-22.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.5.2282-2284.2004"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00981-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00981-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T06:06:18Z","timestamp":1646460378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00981-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1128\/JCM.00981-07"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00981-07","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"2007-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-07-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}